Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

1.

Chemotaxis-driven disease-site targeting of therapeutic adult stem cells in dystrophic epidermolysis bullosa.

Alexeev V, Donahue A, Uitto J, Igoucheva O.

Stem Cell Res Ther. 2016 Aug 27;7(1):124. doi: 10.1186/s13287-016-0388-y.

2.

Quality of Life and Economic Burden in Recessive Dystrophic Epidermolysis Bullosa.

Jeon IK, On HR, Kim SC.

Ann Dermatol. 2016 Feb;28(1):6-14. doi: 10.5021/ad.2016.28.1.6. Epub 2016 Jan 28.

3.

Progress toward Treatment and Cure of Epidermolysis Bullosa: Summary of the DEBRA International Research Symposium EB2015.

Uitto J, Bruckner-Tuderman L, Christiano AM, McGrath JA, Has C, South AP, Kopelan B, Robinson EC.

J Invest Dermatol. 2016 Feb;136(2):352-8. doi: 10.1016/j.jid.2015.10.050. Review.

4.

Lentiviral Engineered Fibroblasts Expressing Codon-Optimized COL7A1 Restore Anchoring Fibrils in RDEB.

Georgiadis C, Syed F, Petrova A, Abdul-Wahab A, Lwin SM, Farzaneh F, Chan L, Ghani S, Fleck RA, Glover L, McMillan JR, Chen M, Thrasher AJ, McGrath JA, Di WL, Qasim W.

J Invest Dermatol. 2016 Jan;136(1):284-92. doi: 10.1038/JID.2015.364.

5.

Lysyl Hydroxylase 3 Localizes to Epidermal Basement Membrane and Is Reduced in Patients with Recessive Dystrophic Epidermolysis Bullosa.

Watt SA, Dayal JH, Wright S, Riddle M, Pourreyron C, McMillan JR, Kimble RM, Prisco M, Gartner U, Warbrick E, McLean WH, Leigh IM, McGrath JA, Salas-Alanis JC, Tolar J, South AP.

PLoS One. 2015 Sep 18;10(9):e0137639. doi: 10.1371/journal.pone.0137639. eCollection 2015.

6.

From Mesoderm to Mesodermatology: Bone Marrow Mesenchymal Cells Heal Skin Wounds.

Tolarova M, Tolar J.

Mol Ther. 2015 Aug;23(8):1283-4. doi: 10.1038/mt.2015.84. No abstract available.

7.

Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms.

Nyström A, Thriene K, Mittapalli V, Kern JS, Kiritsi D, Dengjel J, Bruckner-Tuderman L.

EMBO Mol Med. 2015 Jul 20;7(9):1211-28. doi: 10.15252/emmm.201505061.

8.

Identification of translational dermatology research priorities in the U.K.: results of an electronic Delphi exercise.

Healy E, Brown SJ, Langan SM, Nicholls SG, Shams K, Reynolds NJ; UK TREND.

Br J Dermatol. 2015 Nov;173(5):1191-8. doi: 10.1111/bjd.14022. Epub 2015 Oct 14.

9.

Gene editing toward the use of autologous therapies in recessive dystrophic epidermolysis bullosa.

Perdoni C, Osborn MJ, Tolar J.

Transl Res. 2016 Feb;168:50-8. doi: 10.1016/j.trsl.2015.05.008. Epub 2015 May 27. Review.

PMID:
26073463
10.

Dystrophic epidermolysis bullosa: a review.

Shinkuma S.

Clin Cosmet Investig Dermatol. 2015 May 26;8:275-84. doi: 10.2147/CCID.S54681. eCollection 2015. Review.

11.

Recessive dystrophic epidermolysis bullosa: a review of disease pathogenesis and update on future therapies.

Soro L, Bartus C, Purcell S.

J Clin Aesthet Dermatol. 2015 May;8(5):41-6. Review.

12.

High Local Concentrations of Intradermal MSCs Restore Skin Integrity and Facilitate Wound Healing in Dystrophic Epidermolysis Bullosa.

Kühl T, Mezger M, Hausser I, Handgretinger R, Bruckner-Tuderman L, Nyström A.

Mol Ther. 2015 Aug;23(8):1368-79. doi: 10.1038/mt.2015.58. Epub 2015 Apr 10.

13.

"...Rewritten in the skin": clues to skin biology and aging from inherited disease.

Monnat RJ Jr.

J Invest Dermatol. 2015 Jun;135(6):1484-90. doi: 10.1038/jid.2015.88. Epub 2015 Mar 26. Review.

14.

From marrow to matrix: novel gene and cell therapies for epidermolysis bullosa.

Webber BR, Tolar J.

Mol Ther. 2015 Jun;23(6):987-92. doi: 10.1038/mt.2015.47. Epub 2015 Mar 24. Review.

15.

Placenta-based therapies for the treatment of epidermolysis bullosa.

Nevala-Plagemann C, Lee C, Tolar J.

Cytotherapy. 2015 Jun;17(6):786-95. doi: 10.1016/j.jcyt.2015.03.006. Epub 2015 Mar 18. Review.

16.

A single epidermal stem cell strategy for safe ex vivo gene therapy.

Droz-Georget Lathion S, Rochat A, Knott G, Recchia A, Martinet D, Benmohammed S, Grasset N, Zaffalon A, Besuchet Schmutz N, Savioz-Dayer E, Beckmann JS, Rougemont J, Mavilio F, Barrandon Y.

EMBO Mol Med. 2015 Feb 27;7(4):380-93. doi: 10.15252/emmm.201404353.

17.

Immunogenicity of decidual stromal cells in an epidermolysis bullosa patient and in allogeneic hematopoietic stem cell transplantation patients.

Kaipe H, Carlson LM, Erkers T, Nava S, Molldén P, Gustafsson B, Qian H, Li X, Hashimoto T, Sadeghi B, Alheim M, Ringdén O.

Stem Cells Dev. 2015 Jun 15;24(12):1471-82. doi: 10.1089/scd.2014.0568. Epub 2015 Mar 13.

18.

Transplanted bone marrow-derived circulating PDGFRα+ cells restore type VII collagen in recessive dystrophic epidermolysis bullosa mouse skin graft.

Iinuma S, Aikawa E, Tamai K, Fujita R, Kikuchi Y, Chino T, Kikuta J, McGrath JA, Uitto J, Ishii M, Iizuka H, Kaneda Y.

J Immunol. 2015 Feb 15;194(4):1996-2003. doi: 10.4049/jimmunol.1400914. Epub 2015 Jan 19.

19.

Wound repair and regeneration: mechanisms, signaling, and translation.

Eming SA, Martin P, Tomic-Canic M.

Sci Transl Med. 2014 Dec 3;6(265):265sr6. doi: 10.1126/scitranslmed.3009337. Review.

20.

Preconditioning of mesenchymal stem cells for improved transplantation efficacy in recessive dystrophic epidermolysis bullosa.

Perdoni C, McGrath JA, Tolar J.

Stem Cell Res Ther. 2014 Nov 6;5(6):121. doi: 10.1186/scrt511.

Items per page

Supplemental Content

Write to the Help Desk